First follow-up of neoadjuvant cemiplimab in SCC published last October 2023. 📍 This single arm, multicentre, phase 2 study demonstrated a high rate of pathological complete response (51%) among patients with resectable cutaneous squamous cell carcinoma who received neoadjuvant cemiplimab. 🤓 📍 Results from this follow-up analysis further support the safety and clinical activity of perioperative cemiplimab, with encouraging event-free survival in patients with any degree of pathologic response. 🤓 https://lnkd.in/g2PUuGfP #neoadjuvantimmunotherapy #skincancerdoctor #nonmelanomaskincancer #medicaloncologist
Erika Martinez, MD’s Post
More Relevant Posts
-
Overall survival rate estimated at 24 months was 52.4% with generally tolerated safety profile. At #ASCO24, Dr. David Cognetti presented the updated safety and efficacy findings from an interim evaluation of Rakuten Medical’s open-label Phase 1b/2 study of #photoimmunotherapy using ASP-1929 in combination with anti-PD-1 for recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). Based on these results, Rakuten Medical plans to initiate a new phase 3 clinical trial with a primary endpoint of OS in the second half of 2024. Learn more: https://lnkd.in/gBjPvGzi #Alluminox
To view or add a comment, sign in
-
-
Baseline differences in metabolic profiles of patients with lung squamous cell carcinoma responding or not responding to treatment with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) https://lnkd.in/e5_Skwv2
To view or add a comment, sign in
-
-
Advancing #LiverCancer Diagnosis: Jie Ren et al.'s meta-analysis in #EuropeanRadiology offers valuable insights into using SonoVue® and Sonazoid® for CEUS in detecting hepatocellular carcinoma. Precision in every scan! 🎯🩺 #MedicalImaging 🔗 https://buff.ly/3TKBIg2
To view or add a comment, sign in
-
-
A 90-year-old female patient presented with a three-centimeter squamous cell carcinoma (SCC). The patient underwent electronic brachytherapy treatment schedule with Xstrahl Radiant. See the dramatic before and after photos: https://lnkd.in/eZfZGmnu #ThisIsSkinCancer #NMSC #NMSCAwareness #SkinCancerAwarenessMonth #Xstrahl #RadiantAura #SkinCancer #SkinCancerTreatment #SkinCancerAwareness #squamouscellcarcinoma
To view or add a comment, sign in
-
-
Be sure to read this #clinicalinvestigation 🔍 #Percutaneous Microwave #Ablation Versus Robot-Assisted Partial Nephrectomy for Stage I Renal Cell Carcinoma: A Propensity-Matched Cohort Study Focusing Upon Long-Term Follow-Up of Oncologic Outcomes https://lnkd.in/dPfTsF2C
To view or add a comment, sign in
-
-
Activation of p53 Signaling and Regression of Breast and Prostate Carcinoma Cells by Spirooxindole-Benzimidazole Small Molecules https://lnkd.in/dFZ5H3sx
To view or add a comment, sign in
-
This #radiomics model can be used as a non-invasive tool to predict the Leibovich risk groups for patients with localized clear cell renal cell carcinoma. (Huayun Liu et al.) #InsightsIntoImaging Read it here ➡️ https://buff.ly/3tHTqG4
To view or add a comment, sign in
-
-
Data on the use of rigosertib in patients with RDEB-associated squamous cell carcinoma was presented at the EADV Congress last week: https://lnkd.in/eEuUDJQF EB-associated squamous cell carcinoma is a leading cause of premature death in patients with RDEB, so while we search for a cure, we must also search for treatments to prevent and slow the progression of EB-associated SCC. We are pleased to support this promising work - you can read more about the trial in the Current Research section of our website. #CureEB #ResearchtheCure #EBResearch #Research #RDEB #EADV23
To view or add a comment, sign in
-
Clinical response of T3 squamous cell carcinoma of the tongue, treated with neoadjuvant pembrolizumab-carboplatin-paclitaxel. Significant reduction of the tumor size.
To view or add a comment, sign in
-
-
Going to #ESMO23? We will be there from Oct 20-23. Come to booth 726a and explore the past, present, and potential future treatment options for unresectable hepatocellular carcinoma (uHCC). Plus, you can make an appointment to discuss the latest data. See you soon! https://hubs.ly/Q024bqv90 #ElevatingOutcomes #EveryMeasureMatters #ElevarAtESMO23
To view or add a comment, sign in
-